Eli Lilly has shared positive top-line results from a head-to-head study of its non-covalent Bruton’s tyrosine kinase (BTK) ...

Japan’s evolving approach to market access includes a formal cost-effectiveness analysis (CEA) requirement for certain new ...

AstraZeneca (AZ) has announced that Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) has been recommended by ...

Patient activation is people’s knowledge, skills, confidence and willingness to manage their own health and care. Increasing ...